Bacteriophage Esc-COP-9 Inhibits Pathogenic E. coli Proliferation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preventing and treating pathogenic Escherichia coli infections, such as antibiotics, face challenges due to increasing antibiotic resistance and environmental concerns, necessitating the development of alternative, specifically targeted antibacterial agents.
Innovation Solution
Isolation and utilization of a Siphoviridae bacteriophage Esc-COP-9, which is specifically effective against Escherichia coli, as an active ingredient in compositions for preventing and treating pathogenic Escherichia coli infections, including disinfectants, feed additives, and drinking-water additives.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotics are used for preventing and treating pathogenic Escherichia coli infections, then antibacterial effectiveness is achieved, but antibiotic resistance increases and environmental pollution occurs
Solution Approach 1:
The patent uses bacteriophage Esc-COP-9 as an intermediary agent to eliminate pathogenic Escherichia coli. The bacteriophage specifically infects and kills target bacteria through biological interaction, avoiding the broad-spectrum effects of antibiotics. This intermediary approach provides effective antibacterial action while preventing antibiotic resistance and reducing environmental pollution, as the bacteriophage naturally degrades after use.
2Reliability
If conventional antibiotics are used, then broad-spectrum antibacterial effect is achieved, but commensal bacteria are also affected causing disturbance of normal flora
Solution Approach 1:
The bacteriophage Esc-COP-9 exhibits local quality through its highly specific host range, targeting only pathogenic Escherichia coli strains while leaving commensal bacteria unaffected. This specificity is achieved through the bacteriophage's ability to recognize and bind to unique surface receptors on target bacteria, providing localized antibacterial action that preserves the integrity of normal microbial flora in the animal gut.
3Measurement precision
If bacteriophages are used as antibacterial agents, then specificity against target bacteria is improved, but limited number of types can infect specific bacterium
Solution Approach 1:
The patent applies universality by combining multiple bacteriophages with different specificities into a single composition. This multi-phage formulation can simultaneously target multiple strains of pathogenic Escherichia coli, overcoming the limitation of individual bacteriophages that can infect only specific strains. The composition maintains high specificity for each target strain while achieving broad coverage against various pathogenic E. coli types.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bacteriophage Esc-COP-9 composition exhibits high specificity and effectiveness in inhibiting and killing pathogenic Escherichia coli, reducing side effects on commensal bacteria and environmental impact, offering a sustainable solution for infection control.
Implementation Method 1
Once a bacteriophage infects bacteria, the bacteriophage is proliferated inside the bacterial cell. After proliferation, the progeny of the bacteriophage destroy the bacterial cell wall and escapes from the host bacteria, suggesting that the bacteriophage has the ability to kill bacteria.
Data Source
AI summary
The present invention relates to a Siphoviridae bacteriophage Esc-COP-9 (Accession number: KCTC 13131BP) isolated from nature, which has the ability to specifically kill Escherichia coli and which includes a genome expressed by SEQ. ID. NO: 1, and to a method of preventing and treating a pathogenic Escherichia coli infection using a composition including the same as an active ingredient.